Medical Research

35th Bunshu Medical Award Honors Breakthrough Research
Clinical & Pharma 35th Bunshu Medical Award Honors Breakthrough Research

In the ever-evolving landscape of medical science, few recognitions carry the weight and prestige of the 35th Bunshu Medical Award, recently announced by the Korean Medical Association (KMA) and Korea Boehringer Ingelheim in South Korea. Established in 1990, this esteemed award not only celebrates

Chugai Pharmaceutical: Undervalued Growth Potential in Healthcare
Clinical & Pharma Chugai Pharmaceutical: Undervalued Growth Potential in Healthcare

In the rapidly evolving landscape of global healthcare, few companies have managed to capture investor attention quite like Chugai Pharmaceutical (TSE:4519), a leading Japanese firm with a reputation for innovation and resilience. Amid rising healthcare demands and an aging population worldwide,

Joan Brugge’s Breast Cancer Breakthrough Faces Funding Cuts
Clinical & Pharma Joan Brugge’s Breast Cancer Breakthrough Faces Funding Cuts

In a world where medical advancements hold the promise of transforming lives, the pioneering research of Joan Brugge, co-director of Harvard University’s Ludwig Center, stands out as a beacon of hope in the fight against breast cancer. Her innovative approach focuses on targeting and eliminating

Can Probabilistic Models Redefine Malaria Treatment Failure?
Clinical & Pharma Can Probabilistic Models Redefine Malaria Treatment Failure?

In the relentless fight against malaria, particularly the deadly Plasmodium falciparum strain, late treatment failure stands as a formidable barrier to global health progress, characterized by the reappearance of malaria parasites in the bloodstream after an initially successful drug response. This

How Do Drug Patents Raise Prices and Limit Innovation?
Clinical & Pharma How Do Drug Patents Raise Prices and Limit Innovation?

The pharmaceutical industry stands as a pillar of modern healthcare, tirelessly working to develop life-saving medications through rigorous research and development efforts that often span years and cost billions. Yet, the very system designed to protect and incentivize this innovation—the patent

Why Did the FDA Delay Sanofi’s MS Drug Tolebrutinib Approval?
Clinical & Pharma Why Did the FDA Delay Sanofi’s MS Drug Tolebrutinib Approval?

In the fast-paced realm of pharmaceutical advancements, few stories capture attention like the regulatory journey of Sanofi’s tolebrutinib, a potential game-changer for non-relapsing secondary progressive multiple sclerosis (nrSPMS). This Bruton’s tyrosine kinase (BTK) inhibitor, aimed at slowing

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later